All In Biotech

Drug Trial Radar · NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

736

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.; DualityBio Inc.
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC. The main goals of this study are: * To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival \[rPFS\]). * To find out if BNT324 helps participants live longer overall (overall survival \[OS\]).

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • BNT324Drug

    Intravenous infusion

  • DocetaxelDrug

    Intravenous infusion

  • Prednisone/prednisoloneDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rPFS assessed by BICRTime frame: From randomization to end of study, i.e., up to 58 months
  2. OSTime frame: From randomization to end of study, i.e., up to 58 months

Locations

77 sites in 10 countries. Site status is shown where the registry gives one.

  • Del Sol Research Mgmt LLC

    Tucson, Arizona · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • Florida Cancer Specialists- Fort Myers

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists- St. Petersburg

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists- West Palm Beach

    West Palm Beach, Florida · Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Niles, Illinois · Recruiting

  • Illinois CancerCare PC

    Peoria, Illinois · Recruiting

  • Maryland Oncology Hematology

    Rockville, Maryland · Recruiting

  • NYOH Albany Cancer Center

    Albany, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Oncology/Hematology Care, Inc.

    Cincinnati, Ohio · Recruiting

  • START Carolinas

    Myrtle Beach, South Carolina · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Texas Oncology South Austin

    Austin, Texas · Recruiting

  • Texas Oncology Gulf Coast

    Houston, Texas · Recruiting

  • Texas Oncology, P.A. - Tyler

    Tyler, Texas · Recruiting

  • Texas Oncology - West Texas

    Wichita Falls, Texas · Recruiting

  • Virginia Cancer Specialists PC

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Australia · Recruiting

  • Austin Health

    Heidelberg, Australia · Recruiting

  • Tasman Onco Research Pty Ltd

    Southport, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • AZ Sint-Lucas Gent

    Ghent, Belgium · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Brazil · Recruiting

  • Peking University First Hospital

    Beijing, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Hunan Normal University

    Changsha, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Chongqing Univ. Cancer Hosp.

    Chongqing, China · Recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China · Recruiting

  • Zhejiang Prov. People's Hosp.

    Hangzhou, China · Recruiting

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Hangzhou, China · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.